Respimat
From Wikipedia, the free encyclopedia
 |
This for acronyms may require cleanup to meet Wikipedia's quality standards. (Consider using more specific cleanup instructions.) Please help improve this for acronyms if you can. The talk page may contain suggestions. (December 2010) |
 |
This article is an orphan, as few or no other articles link to it. Please introduce links to this page from related articles; suggestions may be available. (September 2008) |
 |
This article includes a list of references, related reading or external links, but its sources remain unclear because it lacks inline citations. Please improve this article by introducing more precise citations. (December 2010) |
Respimat, or commonly referred to as Respimat SMI (SMI indicates "Soft Mist Inhaler").
Respimat SMI is an advanced drug delivery device in comparison to MDIs(Metered Dose Inhalers) or DPIs(Dry Powder Inhalers) used for the treatment of asthma, chronic obstructive pulmonary disease (COPD), and other respiratory conditions.
Its developer, Boehringer Ingelheim, is currently conducting Phase III clinical trials in the US with a variety of their products, such as Spiriva and Combivent.
[edit] Sources
Boehinger-Ingelheim information
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
-solution.jpg)
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
